Back to Trials
NCT06622070PHASE1RecruitingAccepts Healthy Volunteers

A Study of SPY002-072 in Healthy Volunteers

Spyre Therapeutics, Inc.

Start Date

11/18/2024

Completion Date

8/8/2026

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.

Eligibility Criteria

Age Range: 18 years to 60 years

Inclusion Criteria: * Healthy men and women * Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits Exclusion Criteria: * Participation in more than one cohort * Evidence of clinically significant abnormality or disease * Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent * History of severe allergic reactions or hypersensitivity * Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing

Interventions

DRUG

SPY002-072

OTHER

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

Spyre Site 2

Cypress, California 90630

United States

Spyre Site 1

Montreal, Quebec H3P 3P1

Canada